Novo Nordisk threatened legal and regulatory action against Hims & Hers for selling a $49 compounded copy of Wegovy. Novo accused Hims of duping the public with knock-off products. While NVO shares dropped 7%, HIMS pared earlier gains, trading just 1% higher as the legal battle looms.